Skip to main content

Analytik Jena's FY 2012 Revenues Climb 9 Percent

NEW YORK (GenomeWeb News) – German analytic instrument firm Analytik Jena today said that revenues for its Fiscal Year 2012 increased 9 percent year over year.

For the fiscal year ended Sept. 30, Analytik Jena posted €94.0 million ($124.4 million) in revenues, up from €86.3 million a year ago.

Analytical Instrumentation, the company's largest segment, recorded €60.0 million in revenues, up from €53.2 million a year ago, it said in a statement, while Life Science was virtually flat at €28.2 million, compared to €28.3 million a year ago.

The firm's Optics business had sales of €5.8 million, up from €4.8 million in FY 2011.

"We are working intensively on the international positioning of the comparatively young Life Science segment, and have made progress in some important areas," Analytik Jena CEO Klaus Berka said in the company's statement. "For example, double-digit growth in revenue from PCR products and reagents meant that we were able to compensate for the lower revenue from two subsidiaries."

The firm's R&D costs were reduced 8 percent to €7.3million from €7.9 million a year ago, while SG&A spending rose 9 percent to €33.6 million from €30.9 million.

Analytik Jena's profits attributable to shareholders of the parent firm for FY 2012 increased to €3.2 million, or €.59 per share, compared to a loss of €23,000, or €.03 per share, a year ago.

The firm had €21.5 million in cash and cash equivalents as of the Sept. 30.

"The aim of the Analytik Jena Group for the coming year is to further reinforce and expand our position on the global markets," Berka said. "Our objectives are to generate further revenue growth, exceed the highs recorded in 2011/2012, and ensure qualitative earnings growth."

Revenue growth and profits will be driven by the company's Asian business, which in FY 2012 grew 31 percent year over year, as well as new product launches, it said.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.